Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Take Full Control of Nihon Pharm as Plasma Biz Grows
November 25, 2020
- Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
November 24, 2020
- Takeda Launches Zejula, 2nd PARP Inhibitor in Japan
November 24, 2020
- Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
November 20, 2020
- Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
November 19, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020
- Half of Patients Postpone or Cancel Regular Checkups amid COVID-19: Roche Survey
November 19, 2020
- Number of Patients Treated by Pediatricians Shows Sharp Rebound in October: Survey
November 19, 2020
- 20% of Osteoporosis Patients Reduce/Halt Clinic Visits Amid COVID-19 Pandemic: Survey
November 19, 2020
- Daiichi Sankyo, CureApp Link Up on Cancer Treatment Support App, Eye Clinical Study in FY2021
November 19, 2020
- Nichi-Iko Files Avastin Biosimilar in Japan
November 19, 2020
- As Pfizer/Mylan’s Generics Merger Closed, 4 Viatris Group Firms to Operate Together in Japan
November 18, 2020
- Japan Pharma Market Shrivels 5.1% on COVID-19 Crisis in July-Sept.: IQVIA
November 18, 2020
- Eisai’s Fycompa Gets Pediatric Nod in Europe
November 17, 2020
- Janssen Resumes Japan PI for COVID-19 Vaccine after Temporary Pause
November 17, 2020
- Shionogi Forms Consortium with Univ. of Cambridge, AZ for Digitalized Chemical Synthesis
November 17, 2020
- Medicago, GSK Commence PII of Adjuvanted COVID-19 Vaccine, Progressing into PIII during December
November 17, 2020
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
November 13, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…